Vital3D Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Vital3D Technologies is a private, pre-revenue biotech firm pioneering high-speed, high-precision 3D bioprinting for regenerative medicine and research. Its proprietary FemtoBrush technology integrates Two-Photon Polymerization (2PP) with Spatial Light Modulator (SLM) control, enabling the printing of complex, vascularized structures at a mesoscale. The company's long-term vision is to develop implantable, functional organs, starting with a kidney, while its near-term focus includes bioresorbable stents, advanced organoids, grafts, and vascularized tissue models for drug discovery. Leadership comprises experts in photonics, laser engineering, and business development, positioning the company at the intersection of advanced optics and biotechnology.

Regenerative MedicineOrgan TransplantationCardiovascularDrug Discovery Tools

Technology Platform

Proprietary FemtoBrush technology enabling mesoscale 3D bioprinting via Two-Photon Polymerization (2PP) combined with Spatial Light Modulator (SLM) control. This allows for high-speed printing of complex, vascularized structures with feature sizes down to 1 micron within a large build volume (50x50x100 mm).

Opportunities

The massive global organ shortage and the pharmaceutical industry's need for better predictive human tissue models create a dual market opportunity.

Vital3D's unique mesoscale printing technology could capture significant share in the high-end research tools market while building the foundational IP for future therapeutic implants.

European innovation grants and strategic pharma partnerships offer near-term funding and validation pathways.

Risk Factors

The company faces extreme technical risk in scaling from tissue models to functional, implantable organs, a challenge involving unsolved biological complexities.

Regulatory pathways for bioprinted organs are undefined and will be protracted and costly.

As a pre-revenue start-up, it is highly dependent on securing continuous funding in a competitive investment landscape.

Competitive Landscape

Vital3D competes in the 3D bioprinting space against companies like CELLINK (BICO), Allevi (3D Systems), and Organovo, which offer various extrusion- or DLP-based technologies. Its key differentiator is the combination of 2PP-level resolution with large build volume via FemtoBrush. It also faces competition from academic labs and large medtech firms (e.g., United Therapeutics' organ manufacturing efforts) in the long-term organ replacement arena.

More companies in Europe - Other →